Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification

Overview

Journal Schizophr Bull

Publisher Oxford University Press

Specialty Psychiatry

Date 2013 Sep 19

PMID 24045038

Citations 35

Authors

Saeed Farooq

Ofer Agid

George Foussias

Gary Remington

Affiliations

Soon will be listed here.

Citing Articles

Predicting antipsychotic responsiveness using a machine learning classifier trained on plasma levels of inflammatory markers in schizophrenia.

Yee J, Phua S, See Y, Andiappan A, Goh W, Lee J Transl Psychiatry. 2025; 15(1):51.

PMID: 39952924 PMC: 11828904. DOI: 10.1038/s41398-025-03264-z.

Formal Thought Disorders and Neurocognition in Treatment-Resistant Schizophrenia: Trouble du cours de la pensée et neurocognition dans la schizophrénie réfractaire.

Alarabi M, Burton L, Powell V, Isinger T, Agarwal S, Remington G Can J Psychiatry. 2024; 70(3):229-239.

PMID: 39497431 PMC: 11562935. DOI: 10.1177/07067437241293985.

Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates.

Detanac M, Williams C, Dragovic M, Shymko G, John A Aust N Z J Psychiatry. 2024; 58(12):1080-1089.

PMID: 39198966 PMC: 11585183. DOI: 10.1177/00048674241274314.

Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT).

Farooq S, Hattle M, Kingstone T, Ajnakina O, Dazzan P, Demjaha A Br J Psychiatry. 2024; 225(3):379-388.

PMID: 39101211 PMC: 11536189. DOI: 10.1192/bjp.2024.101.

Polypharmacy to Clozapine Monotherapy in Treatment-Resistant Schizophrenia: A Case Report and Review of the Literature.

Bokhari S, Lutfi L, Elnoor M, Mujahid B, Osman A Cureus. 2024; 16(7):e63871.

PMID: 39100027 PMC: 11298013. DOI: 10.7759/cureus.63871.

References

Insel T, Cuthbert B, Garvey M, Heinssen R, Pine D, Quinn K . Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7):748-51. DOI: 10.1176/appi.ajp.2010.09091379. View

Levine S, Leucht S . Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010; 68(1):86-92. DOI: 10.1016/j.biopsych.2010.01.012. View

Andreasen N, Liu D, Ziebell S, Vora A, Ho B . Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013; 170(6):609-15. PMC: 3835590. DOI: 10.1176/appi.ajp.2013.12050674. View

Girgis R, Phillips M, Li X, Li K, Jiang H, Wu C . Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011; 199(4):281-8. DOI: 10.1192/bjp.bp.110.081471. View

Gonnella J, Hornbrook M, Louis D . Staging of disease. A case-mix measurement. JAMA. 1984; 251(5):637-44. View

Kapur S, Zipursky R, Remington G . Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156(2):286-93. DOI: 10.1176/ajp.156.2.286. View

Pandina G, Bilder R, Turkoz I, Alphs L . Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res. 2013; 143(2-3):312-8. DOI: 10.1016/j.schres.2012.11.031. View

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

Agid O, Kapur S, Remington G . Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2008; 13(3):479-95. DOI: 10.1517/14728214.13.3.479. View

10.

Gaebel W . Status of psychotic disorders in ICD-11. Schizophr Bull. 2012; 38(5):895-8. PMC: 3446222. DOI: 10.1093/schbul/sbs104. View

11.

Farooq S, Taylor M . Clozapine: dangerous orphan or neglected friend?. Br J Psychiatry. 2011; 198(4):247-9. DOI: 10.1192/bjp.bp.110.088690. View

12.

Robinson D, Woerner M, Alvir J, Geisler S, Koreen A, Sheitman B . Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999; 156(4):544-9. DOI: 10.1176/ajp.156.4.544. View

13.

Levander S, Jensen J, Grawe R, Tuninger E . Schizophrenia--progressive and massive decline in response readiness by episodes. Acta Psychiatr Scand Suppl. 2001; (408):65-74. DOI: 10.1034/j.1600-0447.2001.104s408065.x. View

14.

Mouaffak F, Tranulis C, Gourevitch R, Poirier M, Douki S, Olie J . Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006; 29(1):28-33. DOI: 10.1097/00002826-200601000-00009. View

15.

Mathalon D . Challenges associated with application of clinical staging models to psychotic disorders. Biol Psychiatry. 2011; 70(7):600-1. PMC: 4096294. DOI: 10.1016/j.biopsych.2011.08.007. View

16.

Remington G . Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci. 2003; 28(4):275-84. PMC: 165792. View

17.

Agid O, Arenovich T, Sajeev G, Zipursky R, Kapur S, Foussias G . An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72(11):1439-44. DOI: 10.4088/JCP.09m05785yel. View

18.

Mathalon D, Ford J . Neurobiology of schizophrenia: search for the elusive correlation with symptoms. Front Hum Neurosci. 2012; 6:136. PMC: 3360476. DOI: 10.3389/fnhum.2012.00136. View

19.

Leucht S, Barnes T, Kissling W, Engel R, Correll C, Kane J . Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003; 160(7):1209-22. DOI: 10.1176/appi.ajp.160.7.1209. View

20.

Leucht S, Davis J . Are all antipsychotic drugs the same?. Br J Psychiatry. 2011; 199(4):269-71. DOI: 10.1192/bjp.bp.111.095323. View